<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01538472</url>
  </required_header>
  <id_info>
    <org_study_id>ID03-0123</org_study_id>
    <nct_id>NCT01538472</nct_id>
  </id_info>
  <brief_title>Y Zevalin and BEAM in Autologous Stem Cell Transplantation (ASCT) for Lymphoma</brief_title>
  <official_title>Y Zevalin, BEAM and Rituximab In Autologous Stem Cell Transplantation (ASCT) For Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to see if high-dose chemotherapy (BEAM) and
      rituximab, given together with the new drug 90Y Zevalin, followed by a transplant of blood or
      marrow stem cells is safe. Another goal is to learn if this treatment can help decrease the
      chances of the cancer coming back.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BEAM chemotherapy is the standard treatment for lymphoma. BEAM is a combination of
      chemotherapy drugs (carmustine, cytarabine, etoposide, and melphalan). Rituximab is an
      antibody made from human and mouse proteins. It reacts with a certain molecule on the surface
      of lymphoma cells and helps the body's immune system destroy the lymphoma cells. 90Y Zevalin
      is also an antibody made from mouse proteins. However, it has a particle of radiation
      attached to it. 90Y Zevalin works by attaching to lymphoma cells, and the radiation particle
      destroys the lymphoma cell.

      For this study, you will receive rituximab by vein followed by a dose of 111In Zevalin by
      vein (over 15 minutes). 111In Zevalin is different from the study drug (90Y Zevalin). 111In
      Zevalin has a different type of radioactive particle attached to it. This particle does not
      kill lymphoma cells, but it can be &quot;seen&quot; inside the body using a special camera (like an
      x-ray). 111In Zevalin is being used to predict how fast the study drug will travel in the
      body and how long the drug stays in the body. Doctors need to be able to see how much of the
      drug goes to the tumor and how much goes to normal organs to determine if it is safe to give
      90Y Zevalin on an outpatient basis. A scan will be done as soon as 111In Zevalin is given and
      about 2-24 hours later. Scans will also be done 2-3 days later. If the radiation in the 111In
      Zevalin is not a threat to normal organs and bone marrow, you may receive 90Y Zevalin. Seven
      (7) days after the 111In Zevalin injection, you will receive a second dose of rituximab
      followed by a dose of 90Y Zevalin by vein (over 15 minutes).

      Seven (7) days after the 90Y Zevalin injection, you will receive the BEAM combination of
      chemotherapy. You will receive carmustine (over 2 hours) on Day 1 of chemotherapy. You will
      receive cytarabine (over 2 hours) followed by etoposide (over 4 hours) twice a day on Days 2
      through 5. On Day 6, you will receive melphalan (over 20 minutes). A catheter (small flexible
      tube) will be placed in a large vein in your chest so that the chemotherapy drugs can be
      given to you more easily. This is called a central venous catheter. All of the chemotherapy
      drugs will be given through the central venous catheter.

      One day after finishing the chemotherapy, the stem cells that were collected earlier will be
      given back to you by vein over about 30 minutes. Starting on the same day, you will receive
      treatments with G-CSF by injection under the skin once a day. Treatment with G-CSF will
      continue until your blood counts reach a certain level.

      You will receive rituximab by vein (over 6 to 8 hours) on the day after the transplant and
      again 1-week later.

      Blood tests (about 1-2 tablespoons), urine tests, bone marrow collections, and x-rays will be
      done as needed to track the effects of the transplant. You will have transfusions of blood
      and platelets as needed. Blood tests (about 1 tablespoon) will be done once a day while you
      are in the hospital.

      Blood tests (about 1-2 tablespoons), urine tests, bone marrow collections, x-rays, CT scans,
      and PET scans will be done every 3 months for 1 year and then every 6 months for 5 years to
      check on the status of the disease.

      You will be asked to give some extra blood samples (around 1 tablespoon each) at study entry
      and upon return visits to M. D. Anderson. These samples will be used to test for certain
      molecules in the blood (HAMA and soluble CD20) and to check on the level of rituximab in the
      blood.

      Treatment will be given in the hospital at the University of Texas (UT) MD Anderson. You will
      need to stay in the hospital for about 3 to 4 weeks. You should stay in the Houston area for
      about 2 to 4 weeks after the transplant. After that, you will need to return to Houston from
      time to time for blood tests, urine tests, and other exams.

      This is an investigational study. This is an investigational study. 90Y-Zevalin is approved
      by the FDA for relapsed and refractory lymphoma. Its use in this trial, however, is
      investigational. All other drugs used in this study are FDA approved and are commercially
      available. Up to 60 participants will take part in this study. All will be enrolled at MD
      Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival Median</measure>
    <time_frame>Participant followed from baseline treatment to 5 years, with study total period 8 years (study duration)</time_frame>
    <description>Overall survival reported as number of days participants alive following treatment up to 5 years with annual follow up till disease progression. Evaluations done every 3 months for 1 year and then every 6 months for 5 years to check on the status of the disease, with long-term follow up as needed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>3-Year Overall Survival</measure>
    <time_frame>3 years</time_frame>
    <description>Number of participants alive 3 years following treatment. Evaluations done every 3 months for 1 year and then every 6 months to check on the status of the disease.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Y Zevalin + BEAM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rituxan 250 mg/m2 preceding imaging dose of 111In Zevalin (5 mCi); additional infusion 250 mg/m2 Rituxan followed by therapeutic dose of 0.4 mCi/kg 90Y Zevalin received one week after Rituxan/111In Zevalin infusions. One week later, chemotherapy received with BCNU (300 mg/m2, intravenously (IV) day -6) VP-16 (200 mg/m2 IV every 12 hours, days -5 to -2) cytarabine (200 mg/m2 IV every 12 hours, days -5 to -2) and melphalan (140 mg/m2 IV day -1). Autologous stem cell infused on day 0 then Rituximab 1000 mg/m2 on days +1, and +8 post transplantation.
G-CSF 5 mg/kg given daily starting Day 0 till recovery of granulocytes of 4.0 * 109/L.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Y Zevalin</intervention_name>
    <description>Starting dose: 0.4 mCi/kg by vein after Rituxan infusion on Day -14.</description>
    <arm_group_label>Y Zevalin + BEAM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>In Zevalin</intervention_name>
    <description>Imaging dose: 5 mCi by vein following Rituxan infusion on Day -21.</description>
    <arm_group_label>Y Zevalin + BEAM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituxan</intervention_name>
    <description>250 mg/m2 by vein on Day -21 and on Day -14.
1000 mg/m2 by vein on Days +1 and +8.</description>
    <arm_group_label>Y Zevalin + BEAM</arm_group_label>
    <other_name>Rituximab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BCNU</intervention_name>
    <description>300 mg/m2 by vein on Day -6.</description>
    <arm_group_label>Y Zevalin + BEAM</arm_group_label>
    <other_name>Carmustine</other_name>
    <other_name>BiCNU</other_name>
    <other_name>1,3-bis(2-chloroethyl)-1-nitrosourea bis-chloronitrosourea</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VP -16</intervention_name>
    <description>200 mg/m2 by vein every 12 hours on Days -5, -4, -3, and -2.</description>
    <arm_group_label>Y Zevalin + BEAM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ara-C</intervention_name>
    <description>200 mg/m2 by vein every 12 hours on Days -5, -4, -3,and -2.</description>
    <arm_group_label>Y Zevalin + BEAM</arm_group_label>
    <other_name>Cytarabine</other_name>
    <other_name>Cytosar</other_name>
    <other_name>DepoCyt</other_name>
    <other_name>Cytosine Arabinosine Hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>140 mg/m2 by vein on Day -1.</description>
    <arm_group_label>Y Zevalin + BEAM</arm_group_label>
    <other_name>Alkeran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stem Cell Infusion</intervention_name>
    <description>Autologous stem cell infusion on Day 0.</description>
    <arm_group_label>Y Zevalin + BEAM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-CSF</intervention_name>
    <description>5 mg/kg by vein daily starting Day 0 till recovery of granulocytes of 4.0 x 109/L.</description>
    <arm_group_label>Y Zevalin + BEAM</arm_group_label>
    <other_name>Filgrastim</other_name>
    <other_name>Neupogen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Relapsed CD20-positive B-cell non-Hodgkin's lymphoma (NHL) (demonstrated in lymph
             nodes or bone marrow), chemosensitive (at least Partial Remission (PR)).

          2. No anti-cancer therapy started within three weeks, prior to study initiation, and
             fully recovered from all toxicities associated with prior surgery, radiation
             treatments, chemotherapy, or immunotherapy. No prior Rituximab within three weeks of
             starting therapy.

          3. No prior radioimmunoconjugate therapy.

          4. If patients had prior radiation, this should have not involved more than 25% of the
             bone marrow.

          5. An IRB-approved signed informed consent.

          6. Age: 18 to 65 years of age.

          7. Acceptable hematologic status within two weeks prior to patient registration,
             including: Absolute neutrophil count ([segmented neutrophils + bands] * total white
             blood count (WBC)) &gt; 1,500/mm3. Platelet counts &gt; 100,000/mm3.

          8. Patients determined to have &lt;10% bone marrow involvement with lymphoma within four
             weeks before stem cell collection as defined by bilateral aspirates and biopsies.

          9. Prestudy performance status of 0, 1, or 2 according to the World Health Organization
             (WHO).

         10. Female patients included must not be pregnant or lactating.

         11. Men and women or reproductive potential who are following acceptable birth control
             methods (as determined by the treating physician, however abstinence is not an
             acceptable method).

         12. Patients who have previously been treated on Phase II drugs can be included if no
             long-term toxicity is expected, and the patient has been off the drug for four or more
             weeks with no significant post treatment toxicities observed

         13. Patients should have at least 4 * 106 CD34+/kg peripheral stem cells collected.
             Whenever possible, 1 to 2 * 106 CD34+/kg, for the first 10 patients and held for 1
             year in case of graft failure. If graft failure does not occur in the first 10
             patients, backup cells will not be required for subsequent patients.

        Exclusion Criteria:

          1. Patients with impaired bone marrow reserve, as indicated by one or more of the
             following: Prior myeloablative therapies with autologous bone marrow transplantation
             (ABMT) or peripheral blood stem cell (PBSC) rescue Platelet count &lt; 100,000 cells/mm3
             Hypocellular bone marrow Marked reduction in bone marrow precursors of one or more
             cell lines (granulocytic, megakaryocytic, erythroid) History of failed stem cell
             collection of &gt; 4*106 CD34+/kg

          2. Prior radioimmunotherapy.

          3. Presence of central nervous system (CNS) lymphoma.

          4. Patients with chronic lymphocytic lymphoma.

          5. Patients with human immunodeficiency virus (HIV) or acquired immune deficiency
             syndrome (AIDS)-related lymphoma.

          6. Patients with abnormal liver function: total bilirubin &gt; 1.5 mg/dl

          7. Patients with abnormal renal function: serum creatinine &gt; 1.6 mg/dl

          8. Patients who have received prior external beam radiation therapy to &gt;25% of active
             bone marrow (involved field or regional).

          9. Serious nonmalignant disease or infection which, in the opinion of the investigator
             and/or the sponsor, would compromise other protocol objectives.

         10. Corrected carbon monoxide diffusion in the lung (DLCO) &lt;50% and forced expiratory
             volume in 1 second (FEV1) or forced vital capacity (FVC) &lt; 50% predicted.

         11. Cardiac ejection fraction (EF) &lt; 50% by 2-D Echogram.

         12. Pleural effusions.

         13. Prior radiation to lungs.

         14. Abnormal cytogenetics, filter in situ hybridization (FISH) (-5, -7, 11q23)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Issa F. Khouri, MD,BS</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT MD Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Official Website</description>
  </link>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2012</study_first_submitted>
  <study_first_submitted_qc>February 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2012</study_first_posted>
  <results_first_submitted>September 4, 2014</results_first_submitted>
  <results_first_submitted_qc>September 4, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 11, 2014</results_first_posted>
  <last_update_submitted>September 4, 2014</last_update_submitted>
  <last_update_submitted_qc>September 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lymphoma</keyword>
  <keyword>Relapse B-cell CD20+ non-Hodgkin's lymphoma</keyword>
  <keyword>High-dose BEAM chemotherapy</keyword>
  <keyword>Y Zevalin</keyword>
  <keyword>In Zevalin</keyword>
  <keyword>Rituxan</keyword>
  <keyword>Rituximab</keyword>
  <keyword>BCNU</keyword>
  <keyword>1,3-bis(2-chloroethyl)-1-nitrosourea bis-chloronitrosourea</keyword>
  <keyword>Carmustine</keyword>
  <keyword>BiCNU</keyword>
  <keyword>VP-16</keyword>
  <keyword>Ara-C</keyword>
  <keyword>Cytarabine</keyword>
  <keyword>Cytosar</keyword>
  <keyword>DepoCyt</keyword>
  <keyword>Cytosine Arabinosine Hydrochloride</keyword>
  <keyword>Melphalan</keyword>
  <keyword>Alkeran</keyword>
  <keyword>G-CSF</keyword>
  <keyword>Filgrastim</keyword>
  <keyword>Neupogen</keyword>
  <keyword>Stem cell infusion</keyword>
  <keyword>Autologous stem cell transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Carmustine</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: September 30, 2003 to September 17, 2007. All participants enrolled at the University of Texas (UT) MD Anderson Cancer Center.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Y Zevalin + BEAM</title>
          <description>Rituxan 250 mg/m2 preceding imaging dose of 111In Zevalin (5 mCi); additional infusion 250 mg/m2 Rituxan followed by therapeutic dose of 0.4 mCi/kg 90Y Zevalin received one week after Rituxan/111In Zevalin infusions. One week later, chemotherapy received with 1,3-bis(2-chloroethyl)-1-nitrosourea bis-chloronitrosourea (BCNU) (300 mg/m2, intravenously (IV) day -6) VP-16 (200 mg/m2 IV every 12 hours, days -5 to -2) cytarabine (200 mg/m2 IV every 12 hours, days -5 to -2) and melphalan (140 mg/m2 IV day -1). Autologous stem cell infused on day 0 then Rituximab 1000 mg/m2 on days +1, and +8 post transplantation.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Disease Progression</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Y Zevalin + BEAM</title>
          <description>Rituxan 250 mg/m2 preceding imaging dose of 111In Zevalin (5 mCi); additional infusion 250 mg/m2 Rituxan followed by therapeutic dose of 0.4 mCi/kg 90Y Zevalin received one week after Rituxan/111In Zevalin infusions. One week later, chemotherapy received with BCNU (300 mg/m2, intravenously (IV) day -6) VP-16 (200 mg/m2 IV every 12 hours, days -5 to -2) cytarabine (200 mg/m2 IV every 12 hours, days -5 to -2) and melphalan (140 mg/m2 IV day -1). Autologous stem cell infused on day 0 then Rituximab 1000 mg/m2 on days +1, and +8 post transplantation.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53" lower_limit="31" upper_limit="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival Median</title>
        <description>Overall survival reported as number of days participants alive following treatment up to 5 years with annual follow up till disease progression. Evaluations done every 3 months for 1 year and then every 6 months for 5 years to check on the status of the disease, with long-term follow up as needed.</description>
        <time_frame>Participant followed from baseline treatment to 5 years, with study total period 8 years (study duration)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Y Zevalin + BEAM</title>
            <description>Rituxan 250 mg/m2 preceding imaging dose of 111In Zevalin (5 mCi); additional infusion 250 mg/m2 Rituxan followed by therapeutic dose of 0.4 mCi/kg 90Y Zevalin received one week after Rituxan/111In Zevalin infusions. One week later, chemotherapy received with BCNU (300 mg/m2, intravenously (IV) day -6) VP-16 (200 mg/m2 IV every 12 hours, days -5 to -2) cytarabine (200 mg/m2 IV every 12 hours, days -5 to -2) and melphalan (140 mg/m2 IV day -1). Autologous stem cell infused on day 0 then Rituximab 1000 mg/m2 on days +1, and +8 post transplantation.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival Median</title>
          <description>Overall survival reported as number of days participants alive following treatment up to 5 years with annual follow up till disease progression. Evaluations done every 3 months for 1 year and then every 6 months for 5 years to check on the status of the disease, with long-term follow up as needed.</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1299" lower_limit="8" upper_limit="2017"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>3-Year Overall Survival</title>
        <description>Number of participants alive 3 years following treatment. Evaluations done every 3 months for 1 year and then every 6 months to check on the status of the disease.</description>
        <time_frame>3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Y Zevalin + BEAM</title>
            <description>Rituxan 250 mg/m2 preceding imaging dose of 111In Zevalin (5 mCi); additional infusion 250 mg/m2 Rituxan followed by therapeutic dose of 0.4 mCi/kg 90Y Zevalin received one week after Rituxan/111In Zevalin infusions. One week later, chemotherapy received with BCNU (300 mg/m2, intravenously (IV) day -6) VP-16 (200 mg/m2 IV every 12 hours, days -5 to -2) cytarabine (200 mg/m2 IV every 12 hours, days -5 to -2) and melphalan (140 mg/m2 IV day -1). Autologous stem cell infused on day 0 then Rituximab 1000 mg/m2 on days +1, and +8 post transplantation.</description>
          </group>
        </group_list>
        <measure>
          <title>3-Year Overall Survival</title>
          <description>Number of participants alive 3 years following treatment. Evaluations done every 3 months for 1 year and then every 6 months to check on the status of the disease.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event reporting 21 days prior to autologous stem cell transplantation (ASCT) to 8 days post transplant. Overall participation period (inclusive of Y Zevalin, BEAM/Rituximab treatment and ASCT) from March 2004 to November 2011.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Y Zevalin + BEAM</title>
          <description>Rituxan 250 mg/m2 preceding imaging dose of 111In Zevalin (5 mCi); additional infusion 250 mg/m2 Rituxan followed by therapeutic dose of 0.4 mCi/kg 90Y Zevalin received one week after Rituxan/111In Zevalin infusions. One week later, chemotherapy received with BCNU (300 mg/m2, intravenously (IV) day -6) VP-16 (200 mg/m2 IV every 12 hours, days -5 to -2) cytarabine (200 mg/m2 IV every 12 hours, days -5 to -2) and melphalan (140 mg/m2 IV day -1). Autologous stem cell infused on day 0 then Rituximab 1000 mg/m2 on days +1, and +8 post transplantation.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death not related to Common Toxocity Adverse Events (CTCAE)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Secondary Graft Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Death due to Septic Shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Stem cell Infusion Reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary Infiltrates</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Alanine Aminotransferase (ALT) Increase</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Increased Bilirubin</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Alkaline Phosphatase Elevated</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary Frequency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Acute renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin Rash</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Issa Khouri, MD / Professor, Stem Cell Transplant</name_or_title>
      <organization>University of Texas (UT) MD Anderson Cancer Center</organization>
      <phone>713-745-2803</phone>
      <email>CR_Study_Registration@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

